Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape

GSVA: gene set variation analysis for microarray and RNA-Seq data

Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440

Molecular signatures database (MSigDB) 3.0

Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., & Mesirov, J. P. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr260 · Cited by 7,111

Cancer immunotherapy using checkpoint blockade

Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400

The EMBL-EBI search and sequence analysis tools APIs in 2019

Madeira, F., Park, Y. M., Lee, J., Buso, N., Gur, T., Madhusoodanan, N., Basutkar, P., Tivey, A. R. N., Potter, S. C., Finn, R. D., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz268 · Cited by 4,167

T cell exhaustion

Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448

Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease

Shull, M. M., Ormsby, I., Kier, A. B., Pawlowski, S., Diebold, R. J., Yin, M., Allen, R., Sidman, C., Proetzel, G., Calvin, D., et al. (1992) · Nature · doi:10.1038/359693a0 · Cited by 2,985

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851

The TGF-β superfamily as potential therapeutic targets in pancreatic cancer

Tindall, R. R., Bailey, J. M., Cao, Y., & Ko, T. C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1362247 · Cited by 26

Multi-omics analysis elucidates the relationship between intratumor microbiome and host immune heterogeneity in breast cancer

Li, J., Zhang, Y., Cai, Y., Yao, P., Jia, Y., Wei, X., Du, C., & Zhang, S. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.04104-23 · Cited by 27

Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors

Welsh, B. T., Faucette, R., Bilic, S., Martin, C. J., Schürpf, T., Chen, D. J., Nicholls, S. B., Lansita, J. A., & Kalra, A. V. (2021) · International Journal of Toxicology · doi:10.1177/1091581821998945 · Cited by 28

TGF-β in tumor development and progression: mechanisms and therapeutics

Liu, J., Wang, Y., Tang, C., Zhang, L., Xiong, S., Wang, J., & Dong, C. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00403-w · Cited by 26

Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer

Rocconi, R. P., Stevens, E., Bottsford-Miller, J. N., Ghamande, S. A., Elder, J. W., DeMars, L., Munkarah, A. R., Aaron, P. A., Stanbery, L., Wallraven, G., et al. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00317-5 · Cited by 27

Exploiting Canonical TGFβ Signaling in Cancer Treatment

Liu, Q., Chen, G., Moore, J., Guix, I., Placantonakis, D., & Barcellos-Hoff, M. H. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0891 · Cited by 25

Novel Cocktail Therapy Based on a Nanocarrier with an Efficient Transcytosis Property Reverses the Dynamically Deteriorating Tumor Microenvironment for Enhanced Immunotherapy

Wu, J., Guo, Z., Ni, W., Feng, Y., Guo, X., Meng, M., Yuan, Y., Lin, L., Chen, J., Tian, H., et al. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c02724 · Cited by 25

Model-informed approach for risk management of bleeding toxicities for bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1

Vugmeyster, Y., Grišić, A., Wilkins, J. J., Loos, A. H., Hallwachs, R., Osada, M., Venkatakrishnan, K., & Khandelwal, A. (2022) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-022-04468-6 · Cited by 27

Single-cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment

Lim, Y. W., Coles, G. L., Sandhu, S. K., Johnson, D. S., Adler, A. S., & Stone, E. L. (2021) · BMC Biology · doi:10.1186/s12915-021-01034-z · Cited by 26

A mannosylated polymer with endosomal release properties for peptide antigen delivery

Song, K., Nguyen, D. C., Luu, T., Yazdani, O., Roy, D., Stayton, P. S., & Pun, S. H. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.03.004 · Cited by 24

Immunotherapy Updates in Advanced Hepatocellular Carcinoma

Singh, A., Beechinor, R. J., Huynh, J. C., Li, D., Dayyani, F., Valerin, J. B., Hendifar, A. E., Gong, J., & Cho, M. T. (2021) · Cancers · doi:10.3390/cancers13092164 · Cited by 24

Platelets in cancer and immunotherapy: functional dynamics and therapeutic opportunities

Cai, C., Liu, Y., Lu, R., Fan, X., Zeng, S., & Gan, P. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00676-x · Cited by 23

Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer

Ren, Y., Song, J., Li, X., & Luo, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168878 · Cited by 23

The prospect of tumor microenvironment-modulating therapeutical strategies

Eulberg, D., Frömming, A., Lapid, K., Mangasarian, A., & Barak, A. F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1070243 · Cited by 24

Intracellular Adhesion Molecule‐1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8+ T Cells

Lee, S., Kim, Y., Jeon, B., Kim, G., Sohn, J., Yoon, Y., Kim, S., Kim, Y., Kim, H. M., Cha, H., et al. (2023) · Advanced Science · doi:10.1002/advs.202204378 · Cited by 23

TGFβ1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism

Canè, S., Snick, J. V., Uyttenhove, C., Pilotte, L., & den Eynde, B. J. V. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001798 · Cited by 24

Pharmacological combination of nivolumab with dendritic cell vaccines in cancer immunotherapy: An overview

Calmeiro, J., Carrascal, M. A., Tavares, A. R., Ferreira, D. A., Gomes, C. M. F., Cruz, M. T., Falcão, A. C., & Neves, B. M. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105309 · Cited by 22

Megakaryocytes Are Regulators of the Tumor Microenvironment and Malignant Hematopoietic Progenitor Cells in Myelofibrosis

Varricchio, L., & Hoffman, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.906698 · Cited by 21

Comprehensive Analysis of a Cancer-Immunity Cycle–Based Signature for Predicting Prognosis and Immunotherapy Response in Patients With Colorectal Cancer

Hou, Y., Zhang, R., Zong, J., Wang, W., Zhou, M., Yan, Z., Li, T., Gan, W., Lv, S., Zeng, Z., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.892512 · Cited by 21

Development of a TGFβ—IL-2/15 Switch Receptor for Use in Adoptive Cell Therapy

Beck, C., Casey, N. P., Persiconi, I., Moharrami, N. N., Sike, Á., Jin, Y., & Kyte, J. A. (2023) · Biomedicines · doi:10.3390/biomedicines11020459 · Cited by 21

The ovarian cancer-associated microbiome contributes to the tumor’s inflammatory microenvironment

Zhang, M., Mo, J., Huang, W., Bao, Y., Luo, X., & Yuan, L. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1440742 · Cited by 20

Tumor-educated cells in tumor microenvironment: Key drivers of immunotherapy resistance

Zou, J. P., Wang, S., Zhang, Y., Tian, W., Mai, G., Xu, Y., Xiao, W., Graves, E. E., & Wu, F. (2025) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2025.03.12 · Cited by 20

Drug therapy for myocarditis induced by immune checkpoint inhibitors

Wu, Y., Xu, Y., & Xu, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1161243 · Cited by 20

Immunocytokines and cytokine neutralization for cancer immunotherapy

Berraondo, P., Cuesta, R., Aranda, F., Riaño, A. M., Eguren‐Santamaría, I., Luri‐Rey, C., Risson, A., Melero, A., Gomis, G., & Melero, I. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.04.014 · Cited by 19

Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy

Cao, J., Zhang, Z., Zhou, L., Luo, M., Li, L., Li, B., Nice, E. C., He, W., Zheng, S., & Huang, C. (2023) · MedComm · doi:10.1002/mco2.427 · Cited by 19

Loss of LRRC33-Dependent TGFβ1 Activation Enhances Antitumor Immunity and Checkpoint Blockade Therapy

Jiang, A., Qin, Y., & Springer, T. A. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0593 · Cited by 18

Overexpression of MAX dimerization protein 3 (MXD3) predicts poor prognosis in clear cell renal cell carcinoma

Zhang, F., Liu, L., Wu, P., Li, S., & Dong, W. (2021) · Translational Andrology and Urology · doi:10.21037/tau-20-1187 · Cited by 18

The role of interferons in melanoma resistance to immune checkpoint blockade: mechanisms of escape and therapeutic implications

Hargadon, K. M. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20608 · Cited by 18

The role of NK cells in regulating tumorimmunity: current state, challenges and future strategies

Zhu, W., Fan, C., Zhao, Y., Li, W., Niu, J., Dong, S., Yang, Z., & Zhou, W. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03980-y · Cited by 17

Lingual Denervation Improves the Efficacy of Anti-PD-1 Immunotherapy in Oral Squamous Cell Carcinomas by Downregulating TGFβ Signaling

Tao, Z.-Y., Wang, L., Zhu, W., Zhang, G., & Su, Y. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0192 · Cited by 17

Tumour Microenvironment: The General Principles of Pathogenesis and Implications in Diffuse Large B Cell Lymphoma

Sinkarevs, S., Štrumfs, B., Volkova, S., & Štrumfa, I. (2024) · Cells · doi:10.3390/cells13121057 · Cited by 17

Deciphering immune predictors of immunotherapy response: A multiomics approach at the pan-cancer level

Li, X., Pan, L., Li, W., Liu, B., Xiao, C., Chew, V., Zhang, X., Wang, L., Ginhoux, F., Loscalzo, J., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.101992 · Cited by 18

Combined Blockade of GARP:TGF-β1 and PD-1 Increases Infiltration of T Cells and Density of Pericyte-Covered GARP+ Blood Vessels in Mouse MC38 Tumors

Bertrand, C., Meerbeeck, P. V., de Streel, G., Vaherto, N., Benhaddi, F., Rouaud, L., Noël, A., Coulie, P. G., van Baren, N., & Lucas, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.704050 · Cited by 17

Inhibition of TGF-β signaling in bone marrow endothelial cells promotes hematopoietic recovery in acute myeloid leukemia patients

Wang, Z., Zhang, Z., Lyu, Z., Xing, T., Mi, L., Shen, M.-Z., Li, C., Zhang, X., Chen, D., Wang, Y., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217290 · Cited by 16

Harnessing synergistic effects of MMP-2 Inhibition and bFGF to simultaneously preserve and vascularize cardiac extracellular matrix after myocardial infarction

Niu, H. M., Liu, Z., Guan, Y., Wen, J., Dang, Y., & Guan, J. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.10.050 · Cited by 16

Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of cancer

Gupta, A., Budhu, S., Fitzgerald, K., Giese, R., Michel, A. O., Holland, A., Campesato, L. F., Snick, J. V., Uyttenhove, C., Ritter, G., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02773-z · Cited by 16

Decoding cancer’s camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade

Lotsberg, M. L., Rayford, A. J., Thiery, J. P., Belleggia, G., Peters, S. D., Lorens, J. B., Chouaı̈b, S., Terry, S., & Engelsen, A. S. T. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.41 · Cited by 17

Transforming Growth Factor‐β Pathway: Biological Functions and Therapeutic Targets

Mekky, R. H., Fetoh, M. E. A., Faheem, S. A., Radwan, A., Fawzy, M. H., Mustafa, A. M., Said, M. A., Călina, D. C., Sharifi‐Rad, J., & Cho, W. C. S. (2025) · MedComm · doi:10.1002/mco2.70278 · Cited by 15

Nanoparticle‐Based MRI‐Guided Tumor Microenvironment Heating via the Synergistic Effect of Ferroptosis and Inhibition of TGF‐β Signaling

Zhou, R., Liu, Y., Wang, Z., Lv, J., Liao, W., Shen, Z., & Rong, X. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300176 · Cited by 15

Investigating rutin as a potential transforming growth factor‐β type I receptor antagonist for the inhibition of bleomycin‐induced lung fibrosis

Karunarathne, W. A. H. M., Lee, K. T., Choi, Y. H., Kang, C., Lee, M., Kim, S., & Kim, G. (2023) · BioFactors · doi:10.1002/biof.2020 · Cited by 15

Engineering irradiated tumor-derived microparticles as personalized vaccines to enhance anti-tumor immunity

Sun, Y., Tian, Y., Wu, S., Huang, A., Hu, Y., Liao, Z., Swift, M. L., Deng, S., Yang, X., Zhang, B., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101303 · Cited by 15

Bidirectional regulation between tumor cell-intrinsic PD-L1 and TGF-β1 in epithelial-to-mesenchymal transition in melanoma

Li, Z., Wang, F., Dang, J., Cheng, F., & Zheng, F. (2022) · Translational Cancer Research · doi:10.21037/tcr-22-292 · Cited by 14

TGF-β blockade drives a transitional effector phenotype in T cells reversing SIV latency and decreasing SIV reservoirs in vivo

Kim, J., Bose, D., Araínga, M., Haque, M. R., Fennessey, C. M., Caddell, R. A., Thomas, Y., Ferrell, D. E., Ali, S. A., Grody, E. I., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45555-x · Cited by 15

Radiation-primed TGF-β trapping by engineered extracellular vesicles for targeted glioblastoma therapy

Liang, R., Lu, H., Zhu, H., Liang, G., Zhang, J., Gao, J., & Tian, T. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.05.022 · Cited by 16

Red Blood Cell Membrane-Camouflaged Nanoparticles for Synergistic Sonodynamic Therapy and TGF-β Inhibition to Reprogram Immunosuppressive Tumor Microenvironment

Liao, Z., Liao, H., Luo, Y., Chen, S., Chen, M., He, J., Xu, Y., Wang, L., & Niu, C. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c07008 · Cited by 14

Role of non-cardiomyocytes in anticancer drug-induced cardiotoxicity: A systematic review

Xie, S., Yang, Y., Luo, Z., Li, X., Liu, J., Zhang, B., & Li, W. (2022) · iScience · doi:10.1016/j.isci.2022.105283 · Cited by 14

The effects of losartan or angiotensin II receptor antagonists on cartilage: a systematic review

Yamaura, K., Nelson, A. L., Nishimura, H., Rutledge, J. C., Ravuri, S. K., Bahney, C. S., Philippon, M. J., & Huard, J. (2022) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2022.11.014 · Cited by 14

Angiogenesis in heterotopic ossification: From mechanisms to clinical significance

Li, S., Ran, R.-Y., Chen, J., Liu, M., Dang, Y.-M., & Lin, H. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122779 · Cited by 13

ALK5/VEGFR2 dual inhibitor TU2218 alone or in combination with immune checkpoint inhibitors enhances immune-mediated antitumor effects

Kim, N., Lee, J., Kim, S. H., Kang, S.-H., Bae, S., Yu, C.-H., Seo, J., & Kim, H.-T. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03777-4 · Cited by 13

Cryoablation-induced modulation of Treg cells and the TGF-β pathway in lung adenocarcinoma: implications for increased antitumor immunity

Lin, S., Liu, D., Liang, T., Zhuang, Y., Wang, X., Ma, S., Li, Q., & Hu, K. (2025) · BMC Medicine · doi:10.1186/s12916-025-03926-1 · Cited by 14

Spatial Regulation of Cancer-Associated Fibroblasts and Tumor Cells via pH-Responsive Bispecific Antibody Delivery for Enhanced Chemo-Immunotherapy Synergy

Liu, H., Yong, T., Zhang, X., Wei, Z., Bie, N., Xu, S., Zhang, X., Li, S., Zhang, J., Zhou, P., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c13277 · Cited by 13

Revisiting the TGFβ paradox: insights from HPV-driven cancer and the DNA damage response

Barcellos‐Hoff, M. H., & Yom, S. S. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00819-6 · Cited by 13

Anti-TGF-β1 aptamer enhances therapeutic effect of tyrosine kinase inhibitor, gefitinib, on non-small cell lung cancer in xenograft model

Takahashi, M., Hashimoto, Y., & Nakamura, Y. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.06.001 · Cited by 13

Next Generation Immuno-Oncology Strategies: Unleashing NK Cells Activity

Mendoza, A., Álvarez, M., Maria, A. D., Margolin, K. A., Melero, I., & Ascierto, M. L. (2022) · Cells · doi:10.3390/cells11193147 · Cited by 13

Development of the Novel Bifunctional Fusion Protein BR102 That Simultaneously Targets PD-L1 and TGF-β for Anticancer Immunotherapy

Wu, Z.-H., Li, N., Gao, Z., Chen, G., Nie, L., Zhou, Y., Jiang, M.-Z., Chen, Y., Chen, J., Mei, X.-F., et al. (2022) · Cancers · doi:10.3390/cancers14194964 · Cited by 13

Advances in biological and targeted therapies for systemic sclerosis

Mulcaire-Jones, E., Low, A. H. L., Domsic, R. T., Whitfield, M. L., & Khanna, D. (2023) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2023.2196009 · Cited by 13

Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial

Yap, T. A., Sweis, R. F., Vaishampayan, U. N., Kilari, D., Gainor, J. F., McKean, M. A., Barve, M. A., Tarhini, A. A., Bockorny, B., Sonpavde, G., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04157-w · Cited by 14

Tumor microenvironment RNA test to predict immunotherapy outcomes in advanced gastric cancer: The TIMES001 trial

Shi, M., Zeng, D., Luo, H., Xiao, J., Li, Y., Yuan, X., Huang, N., Wu, J., Zheng, S., Wu, J., et al. (2024) · Med · doi:10.1016/j.medj.2024.07.006 · Cited by 12

Unveiling the Tumor Microenvironment Through Fibroblast Activation Protein Targeting in Diagnostic Nuclear Medicine: A Didactic Review on Biological Rationales and Key Imaging Agents

Fouillet, J., Torchio, J., Rubira, L., & Fersing, C. (2024) · Biology · doi:10.3390/biology13120967 · Cited by 12

Natural Killer Cell‐Mediated Antitumor Immunity: Molecular Mechanisms and Clinical Applications

Luo, N., Chen, C., Zhou, W., Hao, J., He, S., Liu, Y., Ku, Y., Huang, L., Zhang, C., Shu, Y., et al. (2025) · MedComm · doi:10.1002/mco2.70387 · Cited by 12

Reciprocal Regulation of Cancer-Associated Fibroblasts and Tumor Microenvironment in Gastrointestinal Cancer: Implications for Cancer Dormancy

Cheng, S.-H., Chiou, H.-Y. C., Wang, J., & Lin, M. (2023) · Cancers · doi:10.3390/cancers15092513 · Cited by 12

Implications of TGFβ Signaling and CDK Inhibition for the Treatment of Breast Cancer

Decker, J. T., Ma, J. A., Shea, L. D., & Jeruss, J. S. (2021) · Cancers · doi:10.3390/cancers13215343 · Cited by 11

Dysregulation of Cytoskeleton Remodeling Drives Invasive Leading Cells Detachment

Peng, J., Chen, W., Cheng, J., Luo, J.-W., & Tzeng, H. (2021) · Cancers · doi:10.3390/cancers13225648 · Cited by 11

Aberrant Activation Mechanism of TGF-β Signaling in Epithelial-mesenchymal Transition

Yuki, R. (2021) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.21-00143 · Cited by 10

Roles of TGF-β in cancer hallmarks and emerging onco-therapeutic design

Dai, X., Hua, D., & Lu, X. (2022) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2022.37 · Cited by 10

Efficacy of Therapies Targeting TGF-β in Solid Tumors: a Systematic Review and Meta-Analysis of Clinical Trials

Rahavi, H., Alizadeh‐Navaei, R., & Tehrani, M. (2023) · Immunotherapy · doi:10.2217/imt-2022-0079 · Cited by 11

Transforming growth factors β and their signaling pathway in renal cell carcinoma and peritumoral space—transcriptome analysis

Kajdaniuk, D., Hudy, D., Strzelczyk, J. K., Młynarek-Śnieżek, K., Słomian, S., Potyka, A., Szymonik, E., Strzelczyk, J., Fołtyn, W., Kos‐Kudła, B., et al. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03350-y · Cited by 9

Overcoming Immune Checkpoint Inhibitor Resistance with Potent, Selective Dual αvβ6/8 Inhibitors Based on Engineered Lasso Peptides

Lechner, A., Jordan, P. A., da Cruz, G. C. M., Lamson, J. S., Gordon, J., Okada, B. K., Anderson, K., Chaudhari, R. R., Rosario, C. J., Mikesell, J., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c06142 · Cited by 9

Recent advances in TGF-β signaling pathway in COVID-19 pathogenesis: A review

Majidpour, M., Azizi, S. G., Davodabadi, F., Akbar-Abad, M. S., Abdollahi, Z., Sargazi, S., & Shahriari, H. (2024) · Microbial Pathogenesis · doi:10.1016/j.micpath.2024.107236 · Cited by 10

Relationship between tumorigenesis, metastasis, immune evasion, and chemoresistance in osteosarcoma therapy

Lim, Y. Y., Zaidi, A. M. A., Haque, M., & Miskon, A. (2023) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2023.149907 · Cited by 9

Cancer-associated fibroblast targeting therapies as a tool to enhance responses to radiotherapy and immunotherapy

Garate-Soraluze, E., Martínez-Zubiaurre, I., & Rodriguez-Ruiz, M. E. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009702 · Cited by 8

Multifaceted Role of the Transforming Growth Factor β on Effector T Cells and the Implication for CAR-T Cell Therapy

de Folmont, A. D. T., Bourhis, J.-H., Chouaı̈b, S., & Terry, S. (2021) · Immuno · doi:10.3390/immuno1030010 · Cited by 9

Inability of Low Oxygen Tension to Induce Chondrogenesis in Human Infrapatellar Fat Pad Mesenchymal Stem Cells

Rahman, S., Szojka, A. R. A., Liang, Y., Kunze, M., Goncalves, V., Mulet‐Sierra, A., Jomha, N. M., & Adesida, A. B. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.703038 · Cited by 8

Jagged-1 is induced by mTOR inhibitors in renal cancer cells through an Akt/ALK5/Smad4-dependent mechanism

Danielpour, D., Corum, S. L., Leahy, P. S., & Bangalore, A. (2022) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2022.100117 · Cited by 8

Killers on the loose: Immunotherapeutic strategies to improve NK cell-based therapy for cancer treatment

Dunai, C., Ames, E., Ochoa, M. C., Fernández-Sendin, M., Melero, I., Simonetta, F., Baker, J. B., & Álvarez, M. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.001 · Cited by 8

Therapeutic Potential of Targeting Transforming Growth Factor-beta (TGF-β) and Programmed Death-ligand 1 (PD-L1) in Pancreatic Cancer

Pourali, G., Zafari, N., Velayati, M., Mehrabadi, S., Maftooh, M., Hassanian, S. M., Mobarhan, M. G., Ferns, G. A., Avan, A., & Khazaei, M. (2023) · Current Drug Targets · doi:10.2174/0113894501264450231129042256 · Cited by 9

The role of cancer‐associated fibroblasts in the tumour microenvironment of urinary system

Hong, R., Yu, P., Zhang, X., Su, P. C., Liang, H., Dong, D. F., Wang, X., & Wang, K. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70299 · Cited by 8

TGFβ2 and TGFβ3 mediate appropriate context-dependent phenotype of rat valvular interstitial cells

Wang, F., Zhang, C., Kwagh, J., Strassle, B. W., Li, J., Huang, M., Song, Y., Lehman, B. L., Westhouse, R. A., Palanisamy, K., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102133 · Cited by 8

Coagulation-Targeted TGF-β Signaling Pathway Inhibitor Nanomedicine for Inhibiting the Growth and Lung Metastasis of Breast Cancer

Xu, Y., Lv, J., Liu, Y., Du, J., Luo, C., Wang, Y., Liu, L., Sakurai, K., Tang, Z., & Chen, X. (2024) · Nano Letters · doi:10.1021/acs.nanolett.4c05355 · Cited by 7

A TGF-β–dominant chemoresistant phenotype of hepatoblastoma associated with aflatoxin exposure in children

Xiao, X., Hao, Y., Cheng, C., Hu, H., Chen, H., Tan, J., Wang, Y., Liu, X., Peng, B., Liao, J., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000534 · Cited by 7

The Combination of Oncolytic Virus and Antibody Blockade of TGF-β Enhances the Efficacy of αvβ6-Targeting CAR T Cells Against Pancreatic Cancer in an Immunocompetent Model

Zhao, Z., Cutmore, L. C., Baleeiro, R. B., Hartlebury, J., Brown, N. F., Chard, L. S., Lemoine, N. R., Wang, Y., & Marshall, J. F. (2025) · Cancers · doi:10.3390/cancers17091534 · Cited by 6

Cancer-associated fibroblasts in non-small cell lung cancer therapy: Challenges and opportunities

Deng, S., Li, Y., Peng, L., Li, J., & Zhang, L. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189568 · Cited by 6

Expanding horizons in cancer therapy by immunoconjugates targeting tumor microenvironments

Fattahi, A. S., Jafari, M., Farahavar, G., Abolmaali, S. S., & Tamaddon, A. M. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104437 · Cited by 6

Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors

Liu, Q., Li, L., Qin, W., & Chao, T. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0281 · Cited by 6

Checkpoint inhibitor rechallenge in advanced endometrial cancer: revisiting the immune landscape beyond first-line therapy

Podder, V., Coleman, R. L., Eskander, R. N., Flint, M., Monk, B. J., & Slomovitz, B. M. (2025) · International Journal of Gynecological Cancer · doi:10.1016/j.ijgc.2025.102124 · Cited by 5

Targeting tumor-draining lymph node to overcome resistance to cancer immunotherapy: an update

Lu, J., Yu, J., Xu, T., Li, Y., Chen, S., Zhou, Q., & Wang, L. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2025.126 · Cited by 5

Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary

Washington, C., Dwivedi, S. K. D., Gunderson-Jackson, C., Walker, J. L., Mannel, R. S., Holman, L. L., Richardson, D. L., Neelakantan, D., Cohoon, A. J., Ding, K., et al. (2025) · Gynecologic Oncology · doi:10.1016/j.ygyno.2025.10.021 · Cited by 5

Immune Imbalance Drives Keloid Pathogenesis: Emerging Targets for Precision Immunotherapy

Chen, Q., Wan, S., Duan, Y., Yan, J., & Zhang, M. (2026) · Advances in Wound Care · doi:10.1177/21621918261417702 · Cited by 5

Selective blockade of latent TGF-β1 activation suppresses tissue fibrosis with good safety

Kanamori, M., Sato, I., Koo, C. X., Sun, Y., Kawauchi, H., Nakagawa, K., Murai, A., Asanuma, K., Gan, S. W., Pang, C. L., et al. (2026) · Communications Medicine · doi:10.1038/s43856-026-01408-w · Cited by 5

Dual inhibition of TGFβ2,3 is severely toxic, whereas selective inhibition of TGFβ1, 2, or 3 and dual inhibition of TGFβ1,2 is generally tolerated in mouse and cynomolgus monkey toxicology studies

Mitra, M. S., Halpern, W., Lepherd, M., Corpuz, J., Adedeji, A. O., Yadav, R., Duarte, I., Sun, T., Arron, J. R., Turley, S. J., et al. (2025) · Toxicological Sciences · doi:10.1093/toxsci/kfaf059 · Cited by 5

Pharmacological targets and mechanism of baicalein in treating breast cancer: a study based on network pharmacology, molecular docking, and bioinformatics analysis

Li, J., Qiao, H., Jia, Y., Yao, P., Wei, X., Feng, Z., Liu, Y., Chang, J., Wang, Q., & Zhang, S. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04479-z · Cited by 5

The role of pro-domains in human growth factors and cytokines

Ratcliff, M., Zhou, R. X., Jermutus, L., & Hyvönen, M. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200663 · Cited by 7

New Potent Inhibitor of Transforming Growth Factor-Beta (TGFβ) Signaling that is Efficacious against Microsatellite Stable Colorectal Cancer Metastasis in Combination with Immune Checkpoint Therapy in Mice

Tauriello, D. V. F., Sancho, E., Byrom, D., Sánchez, C., Salvany, M., Henriques, A. R., Palomo‐Ponce, S., Sevillano, M., Hernando‐Momblona, X., Matarin, J. A., et al. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00374 · Cited by 5

Betulin Attenuates TGF-β1- and PGE2-Mediated Inhibition of NK Cell Activity to Suppress Tumor Progression and Metastasis in Mice

Ogasawara, M., Yamasaki-Yashiki, S., Hamada, M., Yamaguchi-Miyamoto, T., Kawasuji, T., Honda, H., Yanagibashi, T., Ikutani, M., Watanabe, Y., Fujimoto, R., et al. (2022) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b21-00921 · Cited by 5

The Function of the TGFβ Signaling Pathway in Connective Tissue Diseases: From Biology to Clinical Application

Yuan, S., Zhu, W., Wang, Y., & Yu, L. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s539571 · Cited by 5

Drug Repurposing in Oncology: A Strategic Pathway to Unlocking New Therapeutic Potential

Shaik, R., Laddika, S. G., Unnisa, M., Hamza, A., Begum, S., & Sarwar, S. F. (2025) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-025-00895-8 · Cited by 4

A chronic signaling TGFb zebrafish reporter identifies immune response in melanoma

Noonan, H. R., Thornock, A., Barbano, J., Xifaras, M. E., Baron, C. S., Yang, S. P., Koczirka, K., McConnell, A. M., & Zon, L. I. (2024) · eLife · doi:10.7554/elife.83527 · Cited by 5

Mechanism of ELL-associated factor 2 and vasohibin 1 regulating invasion, migration, and angiogenesis in colorectal cancer

Feng, M., Sun, M.-J., Xu, B., Liu, M., Zhang, H., & Wu, C. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i24.3770 · Cited by 4

Harnessing Antitumor Immunity in Ovarian CancerPreprint

Kurnit, K. C., & Odunsi, K. O. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041336 · Cited by 4

TGF-β signaling pathway in the regulations of development and disease

Sun, H., Wei, S., & Xi, Q. (2024) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2024-0326 · Cited by 3

Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors

Welsh, B. T., Faucette, R., Bilic, S., Martin, C. J., Schürpf, T., Chen, D. J., Nicholls, S. B., Lansita, J. A., & Kalra, A. V. (2021) · International Journal of Toxicology · doi:10.1177/1091581821998945 · Cited by 28

Abstract 4090: Defeating primary checkpoint resistance: SRTβ1-Ab3 is a first-in-class, fully human antibody that renders resistant tumors sensitive to anti-PD-1

Schürpf, T., Martin, C. J., Littlefield, C., Chapron, C., Wawersik, S., Kalra, A. V., Simpson, A., Danehy, F. T., Boston, C., Nikiforov, A., et al. (2019) · Immunology · doi:10.1158/1538-7445.sabcs18-4090

TGFβ1-specific antibody spurs anti-tumour immunity

Cully, M. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00058-4 · Cited by 2

773 SOF10, selectively blocking latent TGF-β1 activation, potentiates the efficacy of checkpoint blockade therapy by modulating CAF dynamics and T cell infiltration

Sato, I., Kanamori, M., Nakagawa, K., Sun, S., Asanuma, K., Kawauchi, H., Kayukawa, Y., Matsuo, S., Shida-Kawazoe, M., Kashiwagi, D., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-sitc2024.0773 · Cited by 1

First-in-human phase 1 trial (DRAGON) of SRK-181, a potential first-in-class selective latent TGFβ1 inhibitor, alone or in combination with anti-PD-(L)1 treatment in patients with advanced solid tumors.

Yap, T. A., Barve, M. A., Gainor, J. F., Weekes, C. D., Bockorny, B., Ju, Y., Faucette, R., Bilic, S., Lee-Hoeflich, S. T., Song, G., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.tps3146 · Cited by 7